Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study.
Krupashankar, D S
Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study. [electronic resource] - Journal of the American Academy of Dermatology Sep 2014 - 484-92 p. digital
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1097-6787
10.1016/j.jaad.2014.01.897 doi
Adolescent
Adult
Aged
Antibodies, Monoclonal, Humanized--therapeutic use
Chronic Disease
Double-Blind Method
Female
Humans
Intention to Treat Analysis
Male
Middle Aged
Psoriasis--drug therapy
Severity of Illness Index
Treatment Outcome
Young Adult
Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study. [electronic resource] - Journal of the American Academy of Dermatology Sep 2014 - 484-92 p. digital
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1097-6787
10.1016/j.jaad.2014.01.897 doi
Adolescent
Adult
Aged
Antibodies, Monoclonal, Humanized--therapeutic use
Chronic Disease
Double-Blind Method
Female
Humans
Intention to Treat Analysis
Male
Middle Aged
Psoriasis--drug therapy
Severity of Illness Index
Treatment Outcome
Young Adult